Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naltrexone + aripiprazole
- Development stage
- Phase 2
- Lead developer
- Endo International
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Naltrexone + aripiprazole is a combination therapy being investigated primarily for alcohol dependence treatment. Naltrexone is an opioid antagonist that blocks opioid receptors, reducing alcohol cravings and rewarding effects of alcohol. It's available as oral tablets and monthly injections (Vivitrol). Aripiprazole is an atypical antipsychotic that functions as a dopamine/serotonin system stabilizer, acting as a partial dopamine agonist that blocks dopamine at higher concentrations and augments it at lower concentrations. This combination targets multiple neurotransmitter systems involved in addiction, potentially enhancing efficacy compared to either medication alone.
02
Targets
ADRA1A (α1A)DOR (Opioid Receptor Delta 1)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)KOR (Kappa opioid receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on naltrexone + aripiprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naltrexone + aripiprazole.